Immunoglobulin A vasculitis with intramuscular hemorrhage: a case report

2020 ◽  
Vol 62 (11) ◽  
pp. 1292-1294
Author(s):  
Naoki Kimura ◽  
Takuma Ohnishi ◽  
Satoshi Sato ◽  
Yoji Uejima ◽  
Eisuke Suganuma
Keyword(s):  
Case Report ◽  
Immunoglobulin A ◽  
Intramuscular Hemorrhage ◽  
Immunoglobulin A Vasculitis

scholarly journals Immunoglobulin A Vasculitis Case Report

2020 ◽  
Vol 12 (5) ◽  
pp. 232-235
Author(s):  
Kristin Mannke ◽  
Madeleine Maguire
Keyword(s):  
Case Report ◽  
Immunoglobulin A ◽  
Immunoglobulin A Vasculitis

scholarly journals Alcohol-Associated Immunoglobulin A Vasculitis: A Case Report and Review of the Literature

2020 ◽  
pp. 288-293
Author(s):  
Pallavi Basu ◽  
Eleanor Russell-Goldman ◽  
Rosalynn M. Nazarian ◽  
Shinjita Das
Keyword(s):  
Case Report ◽  
Immunoglobulin A ◽  
Review Of The Literature ◽  
Immunoglobulin A Vasculitis

scholarly journals IgA Vasculitis in Middle Aged Man Followed by Influenza Virus Infection: A Case Report

2018 ◽  
Vol 3 (3) ◽  
pp. 130
Author(s):  
Aqsa Iqbal ◽  
Nicole Stahl ◽  
Erin M Davis
Keyword(s):  
Case Report ◽  
Virus Infection ◽  
Group A Streptococcus ◽  
Severe Disease ◽  
Renal Involvement ◽  
Immunoglobulin A ◽  
Influenza Virus Infection ◽  
Infectious Agent ◽  
Gastrointestinal Lesions ◽  
Immunoglobulin A Vasculitis

Introduction: Immunoglobulin A vasculitis (formerly known as Henoch Schonlein Purpura) is the most common pediatric vasculitis, which occurs typically at the age of 3-15 years. Mononucleosis, group A Streptococcus, Campylobacter and Mycoplasma are some of the common infectious causes of immunoglobulin A vasculitis. Immunoglobulin A vasculitis is a clinically diagnosed disease. Most common clinical features include nonthrombocytopenic nonpruritic palpable purpura, gastrointestinal involvement, arthritis or arthralgia and renal involvement. Biopsy of skin and/or gastrointestinal lesions con rm the diagnosis, although this is not necessary. Immunoglobulin A vasculitis is a self-limiting disease, which resolves spontaneously. Steroids can be used for the treatment of moderate to severe disease and for the prevention of renal complications. Prognosis relies upon various factors among which involvement of kidneys dictates poor prognosis and requires close follow up. Case Presentation: We are presenting a case of immunoglobulin A vasculitis in a 39-year-old German male following in uenza virus infection. The infectious agent that cause immunoglobulin A vasculitis in our patient was In uenza A virus. Biopsy of the skin lesion con rmed the diagnosis of immunoglobulin A vasculitis in our patient. The patient responded to steroids and his skin and GI ndings resolved. Conclusion: Our case report adds to the literature of medicine by describing in uenza virus as a cause of immunoglobulin A vasculitis in young adult patients. Considering immunoglobulin A vasculitis after in uenza and outside of the typical age of 3-15 years, can help to make earlier diagnosis and prevent complications.

scholarly journals Adult onset of Immunoglobulin A vasculitis – A case report

2019 ◽  
Vol 66 (3.4) ◽  
pp. 344-346
Author(s):  
Shusuke Yagi ◽  
Itsuro Endo ◽  
Taichi Murakami ◽  
Tetsuya Hida ◽  
Yousuke Yamamoto ◽  
...  
Keyword(s):  
Case Report ◽  
Immunoglobulin A ◽  
Adult Onset ◽  
Immunoglobulin A Vasculitis

scholarly journals Childhood Immunoglobulin A Vasculitis Associated with COVID-19: A Case Report

2021 ◽  
Vol 11 (01) ◽  
pp. e218-e221
Author(s):  
Osama E. Bekhit ◽  
Abdulelah A. Alfatani ◽  
Mahmoud H.R. Eid ◽  
Shereen A. Mohamed
Keyword(s):  
Case Report ◽  
Immunoglobulin A ◽  
Limited Range ◽  
Nasopharyngeal Swab ◽  
Range Of Movement ◽  
Girl Child ◽  
Child Patient ◽  
Childhood Vasculitis ◽  
Immunoglobulin A Vasculitis

AbstractPrimary immunoglobulin A vasculitis (IgAV) is one the most common childhood vasculitis. A 5-year and 10-month-old girl child patient presented with confluent palpable purple red rash, mainly over both ankles. This was associated with edematous, tender ankles, limited range of movement, and inability to walk. A concomitant coronavirus disease 2019 (COVID-19) was documented by nasopharyngeal swab. This case suggested that COVID-19 can trigger IgAV in children. Hence, awareness of COVID-19 infection in IgAV should be present, and it may be useful to investigate COVID-19 as one of the causes of IgAV, especially in the presence of an epidemic.

scholarly journals AB0012 ROLE OF IRF5 GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1309.1-1310
Author(s):  
S. Remuzgo Martinez ◽  
F. Genre ◽  
V. Pulito-Cueto ◽  
D. Prieto-Peña ◽  
B. Atienza-Mateo ◽  
...  
Keyword(s):  
Inflammatory Diseases ◽  
Disease Onset ◽  
Immunoglobulin A ◽  
Type I ◽  
Research Support ◽  
Development Fund ◽  
European Regional Development Fund ◽  
Social Fund ◽  
Relevant Role ◽  
Immunoglobulin A Vasculitis

Background:Interferon signaling pathway plays a relevant role in autoimmunity. Genetic variants in theinterferon regulatory factor (IRF) 5gene, that encodes the major regulator of the type I interferon induction [1], have been related to the development of several inflammatory diseases [2].Objectives:To determine the influence ofIRF5on Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular disease.Methods:ThreeIRF5polymorphisms (rs2004640, rs2070197 and rs10954213) representative of 3 different haplotype blocks were genotyped in 372 Caucasian patients with IgAV and 876 sex and ethnically matched healthy controls.Results:No statistically significant differences between patients with IgAV and controls were observed when eachIRF5polymorphism was analyzed independently. Similarly, no statistically significant differences between patients with IgAV and controls were found whenIRF5polymorphisms were evaluated combined conforming haplotypes. Additionally, there were no statistically significant differences in genotype, allele and haplotype frequencies ofIRF5when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results do not support an influence ofIRF5on the pathogenesis of IgAV.References:[1]Nat Immunol 2011; 12: 231-8;[2]Arthritis Res Ther 2014; 16: R146.Acknowledgments:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF).Disclosure of Interests:Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Verónica Pulito-Cueto: None declared, D. Prieto-Peña: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, María Jesús Cabero: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, Antonio Navas Parejo: None declared, Javier Sanchez Perez: None declared, Maximiliano Aragües: None declared, Esteban Rubio: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared

Sign in / Sign up

Export Citation Format

Share Document